Researchers thoroughly analyzed adverse events of clinical interest (AECIs) in the VISION trial, including edoema, a MET inhibitor class effect. For patients with MET Exon 14 skipping NSCLC in the phase II VISION trial, the incidence, management, and time to first onset/resolution of all-cause AECIs were analyzed using composite categories (edoema, hypoalbuminemia, creatinine increase, and ALT/AST increase) or individual preferred terms (pleural effusion, nausea, diarrhea, and vomiting). Edema, the most prevalent AECI, was recorded in 69.8% of the 255 individuals studied (median age: 72 years) (grade 3, 9.4%; grade 4, 0%). From the beginning of the first edoema was 7.9 weeks (range: 0.1-58.3). Edema was easily controlled with supportive interventions, dose decrease (18.8%), and treatment interruption (23.1%), and only rarely resulted in treatment cessation (4.3%). Hypoalbuminemia was 23.9% (grade 3, 5.5%); pleural effusion was 13.3% (grade≥3, 5.1%); creatinine increase was 25.9% (grade 3, 0.4%); nausea was 26.7% (grade 3, 0.8%), diarrhoea was 26.3% (grade 3, 0.4%), vomiting was 12.9% (grade 3, 1.2%), and ALT/AST increase was 12.2% (grade≥3, 3.1%). GI AEs usually appear early and disappear within a few weeks. In the largest trial of a MET inhibitor in METex14-skipping NSCLC, tepotinib was well tolerated. In this older population, the most common AEs were mild/moderate and treatable with supportive interventions and dose reduction/interruption, resulting in few withdrawals.